ArticleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2023
Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people.
Article in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Interventional tracheoscopy for management of intratracheal plasmacytoma in a dog.Veterinary research communications · 2026Article
- [Application and challenges of tissue engineered scaffolds in treatment of long-segment laryngotracheal stenosis].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- A bio-adaptive physical hydrogel enables dynamic tissue engineering for tracheal reconstruction.Nature communications · 2025Article
- Real-world oncologic outcomes of thoracoscopic and open tracheal cancer resection.Journal of thoracic disease · 2025Article
- Prognosis of palliative treatment for primary tracheal carcinoma: a two-center retrospective study.Frontiers in oncology · 2025Article
- Primary malignant tumors of the trachea: a retrospective analysis of the clinical data of 79 patients treated in a single center.Frontiers in oncology · 2025Article
- Incidence, risk factors, and epidemiological trends of tracheal cancer: a global analysis.Molecular cancer · 2024Article
- Tissue-engineered tracheal implants: Advancements, challenges, and clinical considerations.Bioengineering & translational medicine · 2024Review
- Treatment outcomes of patients with primary tracheal tumors - analysis of a large retrospective series.BMC cancer · 2024Article
- Tracheal Tumors: Clinical Practice Guidelines for Palliative Treatment and Follow-Up.Oncology reviews · 2024Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
objectivesThe incidence of tracheal cancer is low, few clinicians get much experience and the awareness may be low. Recent data on the treatment and outcome are limited. The aim of the present study was to present updated, national data on the incidence, characteristics, treatment and outcome for patients with tracheal cancer.
methodsAll tracheal cancers registered at the Cancer Registry of Norway in 2000-2020 were extracted. The patient and tumour characteristics age, sex, stage, histology and treatment modality (surgery and radiotherapy) were examined. Overall, median and relative survival were estimated. Cox regression models were used to identify independent prognostic factors.
resultsThe 77 patients diagnosed with tracheal cancer equals a crude incidence rate and an age-standardized incidence rate of 0.075 and 0.046 per 100,000 per year respectively. The mean age was 63.8 years (range: 26-94). The numerical preponderance of men (n = 41) is not statistically significant. Eighteen patients (23.4%) were diagnosed in the localized stage. The 5-year overall survival was 31.7% [95% confidence interval (CI): 21.0-42.9], and in those treated with surgical resection or curative radiotherapy, it was 53.7% (95% CI: 26.1-75.0) and 37.8% (95% CI: 18.8-56.7), respectively. Age, histological type and treatment modality were identified as independent prognostic factors.
conclusionsDespite improved survival, the prognosis for patients with tracheal cancer is still poor. Few are diagnosed in the early stage and thus most are not eligible for curative treatment, mainly surgery. An increased awareness and diagnosis in the earlier stage is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.